{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006957","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.803167+00:00","generated_at":"2026-05-22T03:20:16.858367+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR","bullets":["Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).","GAAP net income $2.4M ($0.07 diluted EPS); non-GAAP adj. net income $57.4M ($1.49 adj. EPS).","Adjusted EBITDA $95.2M (+3% YoY); cash & securities $197.8M, up from $162.8M at Dec 31, 2024.","Board authorized $25M accelerated share repurchase; paid down $16.1M in debt during Q1.","Expanded Jornay PM sales force to ~180 reps; new Chairman, board members, and execs appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006957","json":"https://secwatch.observer/filing/0001558370-25-006957.json","markdown":"https://secwatch.observer/filing/0001558370-25-006957.md","text":"https://secwatch.observer/filing/0001558370-25-006957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/0001558370-25-006957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/coll-20250508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:20:16.858367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}